Jpmorgan Chase & CO Gossamer Bio, Inc. Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
A detailed history of Jpmorgan Chase & CO transactions in Gossamer Bio, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 15,622 shares of GOSS stock, worth $18,121. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,622
Previous 5,138
204.05%
Holding current value
$18,121
Previous $4,000
325.0%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding GOSS
# of Institutions
127Shares Held
162MCall Options Held
2.11MPut Options Held
57.8K-
Octagon Capital Advisors LP New York, NY18.4MShares$21.3 Million6.72% of portfolio
-
Nea Management Company, LLC Timonium, MD18.1MShares$21 Million1.89% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$11.7 Million0.0% of portfolio
-
Arch Venture Management, LLC Chicago, IL8.06MShares$9.34 Million7.27% of portfolio
-
Acadian Asset Management LLC Boston, MA6.36MShares$7.38 Million0.02% of portfolio
About Gossamer Bio, Inc.
- Ticker GOSS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 93,954,000
- Market Cap $109M
- Description
- Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony...